CU24420B1 - Derivados de diheterociclo enlazado a cicloalquilo - Google Patents
Derivados de diheterociclo enlazado a cicloalquiloInfo
- Publication number
- CU24420B1 CU24420B1 CU2016000157A CU20160157A CU24420B1 CU 24420 B1 CU24420 B1 CU 24420B1 CU 2016000157 A CU2016000157 A CU 2016000157A CU 20160157 A CU20160157 A CU 20160157A CU 24420 B1 CU24420 B1 CU 24420B1
- Authority
- CU
- Cuba
- Prior art keywords
- derivatives
- linked
- diheterociclo
- cyclalkyl
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
<p>La presente invención se refiere a compuestos de Ia fórmula (IVa)</p> <p>ESPACIO PARA FÓRMULA</p> <p>, en donde L, D, R1-R8 y x, son como se define en Ia presente. Los derivados de diheterociclo ligados a cicloalquilo novedosos que son útiles en el tratamiento de crecimiento celular anormal, tal como cáncer, en mamíferos.</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461986876P | 2014-04-30 | 2014-04-30 | |
PCT/IB2015/052833 WO2015166373A1 (en) | 2014-04-30 | 2015-04-17 | Cycloalkyl-linked diheterocycle derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20160157A7 CU20160157A7 (es) | 2017-05-10 |
CU24420B1 true CU24420B1 (es) | 2019-06-04 |
Family
ID=53276932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2016000157A CU24420B1 (es) | 2014-04-30 | 2015-04-17 | Derivados de diheterociclo enlazado a cicloalquilo |
Country Status (41)
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106029659B (zh) * | 2014-01-06 | 2020-08-11 | 理森制药股份公司 | 谷氨酰胺酶抑制剂 |
CU24420B1 (es) | 2014-04-30 | 2019-06-04 | Pfizer | Derivados de diheterociclo enlazado a cicloalquilo |
CN107474024B (zh) * | 2016-06-08 | 2022-12-13 | 北京赛林泰医药技术有限公司 | 一种谷氨酰酶抑制剂及其组合物和用途 |
CN110746416A (zh) * | 2019-09-05 | 2020-02-04 | 中国药科大学 | 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途 |
CN116023375A (zh) * | 2021-10-25 | 2023-04-28 | 成都苑东生物制药股份有限公司 | 一种杂环类衍生物、其制备方法及用途 |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2037257A1 (en) | 1970-07-28 | 1972-02-03 | Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt | Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn |
GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
AU658646B2 (en) | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
US5702637A (en) | 1995-04-19 | 1997-12-30 | Minnesota Mining And Manufacturing Company | Liquid crystal compounds having a chiral fluorinated terminal portion |
EP0821671B1 (en) | 1995-04-20 | 2000-12-27 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
JPH09104838A (ja) | 1995-10-09 | 1997-04-22 | Mitsui Toatsu Chem Inc | 水性塗料用樹脂組成物 |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
PT780386E (pt) | 1995-12-20 | 2003-02-28 | Hoffmann La Roche | Inibidores de metaloprotease de matriz |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
AU3766897A (en) | 1996-07-13 | 1998-02-09 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
EP0912572B1 (en) | 1996-07-13 | 2003-01-15 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
EA199900036A1 (ru) | 1996-07-18 | 1999-06-24 | Пфайзер Инк | Ингибиторы металлопротеаз матрикса на основе фосфинатов, фармацевтическая композиция, способ лечения |
JP2000501423A (ja) | 1996-08-23 | 2000-02-08 | ファイザー インク. | アリールスルホニルアミノヒドロキサム酸誘導体 |
ATE272640T1 (de) | 1997-01-06 | 2004-08-15 | Pfizer | Cyclische sulfonderivate |
CA2279276C (en) | 1997-02-03 | 2005-09-13 | Pfizer Products Inc. | Arylsulfonylamino hydroxamic acid derivatives |
JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | N−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
JP3710489B2 (ja) | 1997-02-11 | 2005-10-26 | ファイザー・インク | アリールスルホニルヒドロキサム酸誘導体 |
EP0984930B1 (en) | 1997-05-07 | 2005-04-06 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
JP2002501532A (ja) | 1997-05-30 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | 新規血管形成阻害薬 |
AU8816298A (en) | 1997-08-22 | 1999-03-16 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
JP2001518470A (ja) | 1997-09-26 | 2001-10-16 | メルク エンド カムパニー インコーポレーテッド | 新規な血管形成阻害剤 |
HUP0100287A3 (en) | 1997-11-11 | 2003-04-28 | Pfizer Prod Inc | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
IL139934A (en) | 1998-05-29 | 2007-10-31 | Sugen Inc | History 2 - Indulinone converted to pyrrole and pharmaceutical preparations containing them |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
CN1330640C (zh) | 2000-06-22 | 2007-08-08 | 辉瑞产品公司 | 用于治疗异常细胞生长的取代的双环衍生物 |
US6451828B1 (en) | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
AR042586A1 (es) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
DE10109807A1 (de) | 2001-03-01 | 2002-09-05 | Wella Ag | Verbrückte Diaminopyrazole und diese Verbindungen enthaltende Färbemittel |
US7029729B2 (en) | 2003-02-24 | 2006-04-18 | 3M Innovative Properties Company | Cholesteric liquid crystal additives |
ES2279446T3 (es) | 2003-08-15 | 2007-08-16 | MERCK & CO., INC. | Antagonistas nmda/nr2b de 4-cicloalquilaminopirazolo pirimidina. |
JP2008512346A (ja) | 2004-09-09 | 2008-04-24 | アステラス製薬株式会社 | Vap−1阻害活性を有するチアゾール誘導体 |
WO2008104077A1 (en) | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
US20120077814A1 (en) | 2010-09-10 | 2012-03-29 | Zhong Wang | Sulfonamide, sulfamate, and sulfamothioate derivatives |
DK2782570T3 (da) * | 2011-11-21 | 2019-12-09 | Calithera Biosciences Inc | Heterocykliske hæmmere af glutaminase |
US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
US20130246300A1 (en) | 2012-03-13 | 2013-09-19 | American Express Travel Related Services Company, Inc. | Systems and Methods for Tailoring Marketing |
WO2014031933A2 (en) | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
EA029707B1 (ru) * | 2012-11-16 | 2018-05-31 | Калитера Байосайенсиз, Инк. | Гетероциклические ингибиторы глютаминазы |
US9303002B2 (en) | 2012-11-21 | 2016-04-05 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
US9029531B2 (en) * | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
WO2014089048A1 (en) | 2012-12-03 | 2014-06-12 | Calithera Biosciences, Inc. | Treatment of cancer with heterocyclic inhibitors of glutaminase |
US9868705B2 (en) * | 2013-09-27 | 2018-01-16 | The Board Of Trustees Of The University Of Illinois | Tetra-aryl cyclobutane inhibitors of androgen receptor action for the treatment of hormone refractory cancer |
WO2015061432A1 (en) | 2013-10-25 | 2015-04-30 | Calithera Biosciences, Inc. | Treatment of viral infections with inhibitors of glutaminase |
CN106029659B (zh) * | 2014-01-06 | 2020-08-11 | 理森制药股份公司 | 谷氨酰胺酶抑制剂 |
US20150258082A1 (en) | 2014-03-14 | 2015-09-17 | Francesco Parlati | Combination therapy with glutaminase inhibitors |
JP6602364B2 (ja) | 2014-03-21 | 2019-11-06 | アジオス ファーマシューティカルズ, インコーポレイテッド | 化合物及びそれらの使用の方法 |
CU24420B1 (es) | 2014-04-30 | 2019-06-04 | Pfizer | Derivados de diheterociclo enlazado a cicloalquilo |
CN107027291B (zh) | 2014-06-13 | 2020-10-30 | 卡利泰拉生物科技公司 | 用谷氨酰胺酶抑制剂的组合疗法 |
WO2016014890A1 (en) | 2014-07-24 | 2016-01-28 | Calithera Biosciences, Inc. | Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase |
BR112017020780A2 (pt) | 2015-03-30 | 2018-06-26 | Calithera Biosciences Inc | métodos de administração de inibidores de glutaminase |
AU2016246521B2 (en) | 2015-04-06 | 2020-07-09 | Calithera Biosciences, Inc. | Treatment of lung cancer with inhibitors of glutaminase |
US10884952B2 (en) | 2016-09-30 | 2021-01-05 | Intel Corporation | Enforcing memory operand types using protection keys |
JP6943759B2 (ja) | 2017-12-28 | 2021-10-06 | 株式会社東海理化電機製作所 | シフト装置 |
-
2015
- 2015-04-17 CU CU2016000157A patent/CU24420B1/es unknown
- 2015-04-17 WO PCT/IB2015/052833 patent/WO2015166373A1/en active Application Filing
- 2015-04-17 CA CA2947130A patent/CA2947130C/en not_active Expired - Fee Related
- 2015-04-17 MX MX2016014143A patent/MX2016014143A/es unknown
- 2015-04-17 AP AP2016009530A patent/AP2016009530A0/en unknown
- 2015-04-17 RS RS20191540A patent/RS59617B1/sr unknown
- 2015-04-17 HU HUE15726701A patent/HUE046518T2/hu unknown
- 2015-04-17 PT PT157267014T patent/PT3137460T/pt unknown
- 2015-04-17 LT LT15726701T patent/LT3137460T/lt unknown
- 2015-04-17 UA UAA201610872A patent/UA117861C2/uk unknown
- 2015-04-17 CR CR20160497A patent/CR20160497A/es unknown
- 2015-04-17 KR KR1020167033037A patent/KR20160149256A/ko not_active Application Discontinuation
- 2015-04-17 JP JP2016564569A patent/JP6574203B2/ja not_active Expired - Fee Related
- 2015-04-17 EA EA201650003A patent/EA033919B1/ru not_active IP Right Cessation
- 2015-04-17 TN TN2016000459A patent/TN2016000459A1/en unknown
- 2015-04-17 PL PL15726701T patent/PL3137460T3/pl unknown
- 2015-04-17 MA MA39926A patent/MA39926B1/fr unknown
- 2015-04-17 MA MA049708A patent/MA49708A/fr unknown
- 2015-04-17 EP EP19172254.5A patent/EP3556757A1/en not_active Withdrawn
- 2015-04-17 US US15/306,979 patent/US20170050958A1/en not_active Abandoned
- 2015-04-17 ES ES15726701T patent/ES2759434T3/es active Active
- 2015-04-17 SG SG11201608634RA patent/SG11201608634RA/en unknown
- 2015-04-17 GE GEAP201514314A patent/GEP20186879B/en unknown
- 2015-04-17 PE PE2016002145A patent/PE20161436A1/es unknown
- 2015-04-17 MD MDA20160111A patent/MD20160111A2/ro not_active Application Discontinuation
- 2015-04-17 CN CN201580022426.XA patent/CN106232598B/zh not_active Expired - Fee Related
- 2015-04-17 BR BR112016024513A patent/BR112016024513A2/pt not_active IP Right Cessation
- 2015-04-17 DK DK15726701.4T patent/DK3137460T3/da active
- 2015-04-17 EP EP15726701.4A patent/EP3137460B1/en active Active
- 2015-04-17 SI SI201530998T patent/SI3137460T1/sl unknown
- 2015-04-17 NZ NZ72549615A patent/NZ725496A/en not_active IP Right Cessation
- 2015-04-17 AU AU2015254943A patent/AU2015254943B2/en not_active Ceased
-
2016
- 2016-10-05 CL CL2016002532A patent/CL2016002532A1/es unknown
- 2016-10-07 PH PH12016501997A patent/PH12016501997A1/en unknown
- 2016-10-21 EC ECIEPI201683017A patent/ECSP16083017A/es unknown
- 2016-10-26 NI NI201600163A patent/NI201600163A/es unknown
- 2016-10-28 SV SV2016005310A patent/SV2016005310A/es unknown
- 2016-10-28 GT GT201600232A patent/GT201600232A/es unknown
- 2016-10-28 DO DO2016000293A patent/DOP2016000293A/es unknown
- 2016-10-30 IL IL248629A patent/IL248629B/en active IP Right Grant
-
2017
- 2017-06-09 HK HK17105698.5A patent/HK1232212A1/zh not_active IP Right Cessation
- 2017-11-29 US US15/826,027 patent/US10125130B2/en active Active
-
2018
- 2018-10-11 US US16/157,618 patent/US20190040055A1/en not_active Abandoned
-
2019
- 2019-05-20 US US16/416,997 patent/US10676471B2/en active Active
- 2019-08-15 JP JP2019149123A patent/JP2019214597A/ja not_active Ceased
- 2019-11-13 HR HRP20192056TT patent/HRP20192056T1/hr unknown
- 2019-11-28 CY CY20191101248T patent/CY1122439T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP22091792A (es) | Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroplastos | |
CU24408B1 (es) | Compuestos de dihidroisoquinolinona sustituida | |
CL2017002483A1 (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
CR20150279A (es) | Lactamas fusionadas de arilo y heteroarilo | |
ECSP16061758A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
CU24410B1 (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
UY33199A (es) | 5-alquinil-pirimidinas. | |
CR20210079A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
CL2015001246A1 (es) | Derivados de bendamustina y los metodos de su uso | |
EA201691194A1 (ru) | Стимуляторы ргц | |
CU24263B1 (es) | Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer | |
CU24402B1 (es) | 2,6 purinas di-sustituidas útiles en el tratamiento de trastornos proliferativos tales como cáncer | |
CO2017001528A2 (es) | Compuestos novedosos de pirimidina sustituidos | |
CO2017001506A2 (es) | Compuestos novedosos de pirimidina sustituidos | |
PH12017500839A1 (en) | Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2 | |
DOP2015000060A (es) | Profármacos de aminoquinazolina inhibidora de cinasa | |
CU24420B1 (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
CL2016001623A1 (es) | Compuestos de benzamida y nicotinamida y métodos para usar los mismos. | |
DOP2015000298A (es) | Compuestos nuevos para el tratamiento del cáncer | |
DOP2016000211A (es) | Pirazinas moduladoras de gpr6 | |
DOP2016000021A (es) | Imidazotiazol sulfonamidas como nematicidas | |
IN2014CH00151A (es) | ||
SV2016005302A (es) | Tinturas reactivas fluorescentes, proceso para su producción y su uso | |
MX2016005223A (es) | Tinturas dispersas, su preparacion y su uso. | |
MX2015012523A (es) | Metodos para elaborar composiciones antineoplasicas. |